Traversa Sergio's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed Sep 11, 2024
- Accession no.
- 0001213900-24-077795
- Filed
- Sep 11, 2024
- Trade date
- Sep 9-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $395.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Traversa SergioCIK 0001565832 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Common Stock | PPurchaseAcquired | +55,579 | $2.71 | +$150,619.09 | 299,603 | Direct | |
| Sep 10, 2024 | Common Stock | PPurchaseAcquired | +33,014 | $2.75 | +$90,788.5 | 332,617 | Direct | |
| Sep 11, 2024 | Common Stock | PPurchaseAcquired | +51,407 | $2.99 | +$153,706.93 | 384,024 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.